Faculty

Institution

Unit

Venue

Jie Wu

Professor of Pathology

University of Oklahoma

Affiliations

HEALTH SCIENCES CENTER CAMPUS COLLEGES

College of Medicine

Health Sciences Center Graduate College

College of Medicine

Pathology

Jie Wu is currently serving as a College Of Medicine Professor of Pathology at University of Oklahoma.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Jie Wu

University of Oklahoma

Professor of Pathology

You can click a keyword to filter the displayed items

molecular biology pharmacology cancer research oncology biochemistry cell biology cancer biology enzyme inhibition cell signaling medicinal research tumor biology signal transduction oncogenes gene expression cancer treatment protein science protein phosphorylation receptor tyrosine kinases leukemia biological chemistry cancer genetics enzymes molecular cancer molecular and cellular biology signaling pathways molecular cell biology pharmacotherapy cell regulation molecular physiology thoracic oncology protein function tumor targeting anti-cancer agents structural molecular biology cell death molecular regulation novel therapies vascular biology redox biology cancer discovery tumor suppressors hematological malignancies apoptosis drug targeting cancer genomics redox signaling cytokines inhibitory activity cellular biology insulin signaling malignant blood disorders myeloid neoplasia epidermal growth factor map kinase structural basis lysophosphatidic acid treatment development enzyme specificity skeletal muscle receptor (biochemistry) cellular immune responses remedial action genitourinary cancers oncogenic agent map kinase kinase mitogen-activated protein kinase tyrosine phosphorylation lung adenocarcinoma g-quadruplex aptamer ret aberrant cancers kinase activity egf-activated map kinase non-small-cell lung cancer targeted therapy treatment landscape protein kinase cascades surgical oncology medicine gastrointestinal oncology behavioral pediatrics pediatrics pancreatic cancer cancer care chronic pain palliative care

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 7211: Proteolysis Targeting Chimeras (Protacs) of Oncogenic Ret Protein. Cancer Research (2025)

Shriya PandeyYafeng WangXueqing HuUjjwol KhatriTao ShenVivek SubbiahBlaine H. MooersTing ChaoShaohui WangHuaxuan YuXingmin SunJianfeng CaiJie Wu

cancer researchcancer biologyoncogenic ret protein

Development of Physiologically Based Pharmacokinetic Models for Ret Inhibitors to Predict Brain Distribution. (2025)

Seongjun JoHerman SintimJie WuSukyung Woo

pharmacologyret inhibitorspharmacokinetic modelsphysiologically-based pharmacokinetic modelingpharmacokineticsbrain distribution

Identification of Alkynyl Nicotinamide Hsn748 as a Ret Solvent-Front Mutant Inhibitor With Intracranial Efficacy. RSC Medicinal Chemistry (2025)

Ujjwol KhatriNeetu DayalKofi B. OwusuMandeep Kaur HunjanShriya PandeyHaley A. HarperCarli McMahanBennett D. ElzeyTao ShenXueqing HuKurt W. EvansAhmed El-SheikhJo Seong junFrederick W. HoltsbergM. Javad AmanFunda Meric-BernstamSukyung WooHerman O SintimJie Wu

neuropharmacologybiochemistrymolecular pharmacologybiomolecular engineeringvascular biologydrug developmentmedicinal chemistrypharmacologyintracranial efficacypeptide therapeuticspharmaceutical researchpeptide sciencedrug discoverypharmaceutical chemistryenzyme inhibitionpeptidesmedicinal researchrational drug designtherapeutic targets

Selpercatinib Mitigates Cancer Cachexia Independent of Anti-Tumor Activity in the Ht1080 Tumor Model. Cancer Letters (2025)

Ujjwol KhatriMohamed A GoudaShriya PandeyNeeraj K ChauhanTao ShenXueqing HuMin LiSuming HuangVivek SubbiahJie Wu

tumor targetinganti-tumor activitycancer treatmentselpercatinib mitigates cancercancer researchoncologycancer letterbiochemistrytumor biology

Abstract 4660: Characterization of a Nicotinamide-Based Kinase Inhibitor Hsn748 for Inhibition of Ret-Driven Tumors. Cancer Research (2024)

Ujjwol KhatriNeetu DayalTao ShenXueqing HuHerman SintimJie Wu

tumor targetingdrug targetinganti-cancer agentsclinical researchcancer biologymolecular cancercancer researchtumor biologypharmacologycancer treatmentoncologyret-driven tumorspharmacotherapycancer carehealth sciencesdrug discoveryenzyme inhibitionradiation oncologymedicinal research

Adaptive Darwinian Off-Target Resistance Mechanisms to Selective Ret Inhibition in Ret Driven Cancer. npj Precision Oncology (2024)

Vivek SubbiahMohamed A. GoudaJ. Bryan IorgulescuRamona DaduKeyur PatelSteven ShermanMaria CabanillasMimi HuLuz E. CastellanosBehrang AminiFunda Meric-BernstamTao ShenJie Wu

oncologyret inhibitionret driven cancer

Targeting Oncogenic Ret Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the Protein. Journal of Medicinal Chemistry (2024)

Yafeng WangXueqing HuShriya PandeyUjjwol KhatriTao ShenVivek SubbiahBlaine H. M. MooersTing ChaoShaohui WangHuaxuan YuXingmin SunJie WuJianfeng Cai

medicinal chemistryoncogenesoncogenic ret kinaseenzyme inhibitionbiochemistrymolecular biologykinase activityprotein sciencetherapeutic targetsinhibitory activity

Adaptive Responses to Ret-Targeted Cancer Therapy. Cancer Letters (2023)

Jie Wu

ret-targeted cancer therapycancer researchadaptive responsescancer treatment

Exceptional Responses to Selpercatinib in Ret Fusion–Driven Metastatic Pancreatic Cancer. JCO Precision Oncology (2023)

Deepak BhamidipatiSireesha YedururiJason HuseSri Veda ChinapuvvulaJie WuVivek Subbiah

health sciencescancer researchoncologymetastasispancreatic cancer

Exceptional Response to Selpercatinib in Ret-Fusion Driven Metastatic Pancreatic Cancer. JCO Precis Oncol. (2023)

gastrointestinal oncologypathologyexceptional responsemolecular cancercancer treatmentcancer cellsoncogenesoncologymetastasiscell biologypancreatic cancer

1
2
3
4
5
13
10 / page

Jie Wu

Professor of Pathology

University of Oklahoma

Affiliations

HEALTH SCIENCES CENTER CAMPUS COLLEGES

College of Medicine

Health Sciences Center Graduate College

College of Medicine

Pathology

Jie Wu is currently serving as a College Of Medicine Professor of Pathology at University of Oklahoma.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Jie Wu

University of Oklahoma

Professor of Pathology

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Abstract 7211: Proteolysis Targeting Chimeras (Protacs) of Oncogenic Ret Protein. Cancer Research (2025)

Shriya PandeyYafeng WangXueqing HuUjjwol KhatriTao ShenVivek SubbiahBlaine H. MooersTing ChaoShaohui WangHuaxuan YuXingmin SunJianfeng CaiJie Wu

cancer researchcancer biologyoncogenic ret protein

Development of Physiologically Based Pharmacokinetic Models for Ret Inhibitors to Predict Brain Distribution. (2025)

Seongjun JoHerman SintimJie WuSukyung Woo

pharmacologyret inhibitorspharmacokinetic modelsphysiologically-based pharmacokinetic modelingpharmacokineticsbrain distribution

Identification of Alkynyl Nicotinamide Hsn748 as a Ret Solvent-Front Mutant Inhibitor With Intracranial Efficacy. RSC Medicinal Chemistry (2025)

Selpercatinib Mitigates Cancer Cachexia Independent of Anti-Tumor Activity in the Ht1080 Tumor Model. Cancer Letters (2025)

Ujjwol KhatriMohamed A GoudaShriya PandeyNeeraj K ChauhanTao ShenXueqing HuMin LiSuming HuangVivek SubbiahJie Wu

tumor targetinganti-tumor activitycancer treatmentselpercatinib mitigates cancercancer researchoncologycancer letterbiochemistrytumor biology

Abstract 4660: Characterization of a Nicotinamide-Based Kinase Inhibitor Hsn748 for Inhibition of Ret-Driven Tumors. Cancer Research (2024)

Ujjwol KhatriNeetu DayalTao ShenXueqing HuHerman SintimJie Wu

Adaptive Darwinian Off-Target Resistance Mechanisms to Selective Ret Inhibition in Ret Driven Cancer. npj Precision Oncology (2024)

Vivek SubbiahMohamed A. GoudaJ. Bryan IorgulescuRamona DaduKeyur PatelSteven ShermanMaria CabanillasMimi HuLuz E. CastellanosBehrang AminiFunda Meric-BernstamTao ShenJie Wu

oncologyret inhibitionret driven cancer

Targeting Oncogenic Ret Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the Protein. Journal of Medicinal Chemistry (2024)

Yafeng WangXueqing HuShriya PandeyUjjwol KhatriTao ShenVivek SubbiahBlaine H. M. MooersTing ChaoShaohui WangHuaxuan YuXingmin SunJie WuJianfeng Cai

medicinal chemistryoncogenesoncogenic ret kinaseenzyme inhibitionbiochemistrymolecular biologykinase activityprotein sciencetherapeutic targetsinhibitory activity

Adaptive Responses to Ret-Targeted Cancer Therapy. Cancer Letters (2023)

Jie Wu

ret-targeted cancer therapycancer researchadaptive responsescancer treatment

Exceptional Responses to Selpercatinib in Ret Fusion–Driven Metastatic Pancreatic Cancer. JCO Precision Oncology (2023)

Deepak BhamidipatiSireesha YedururiJason HuseSri Veda ChinapuvvulaJie WuVivek Subbiah

health sciencescancer researchoncologymetastasispancreatic cancer

Exceptional Response to Selpercatinib in Ret-Fusion Driven Metastatic Pancreatic Cancer. JCO Precis Oncol. (2023)

gastrointestinal oncologypathologyexceptional responsemolecular cancercancer treatmentcancer cellsoncogenesoncologymetastasiscell biologypancreatic cancer

1
2
3
4
5
13
10 / page

Similar Faculty Members

Besim Ogretmen, Ph.D

Institution

Medical University of South Carolina

cancer pathogenesis

cancer biology

Rafael Fridman

Institution

Wayne State University

proteases

cancer biology

Lee Graves

Institution

University of North Carolina at Chapel Hill

molecular biology

pharmacology

Adrienne Cox

Institution

University of North Carolina at Chapel Hill

molecular cancer

carcinogenesis

Dafna Bar-Sagi

Institution

New York University

oncogene

oncogene function

Shantu Amin

Institution

Pennsylvania State University

cancer letter

polycyclic aromatic hydrocarbon

Raul A. Urrutia, MD

Institution

Medical College of Wisconsin

epigenetics

histone deacetylase

Michael Hollingsworth

Institution

University of Nebraska Medical Center

pathology

immunology

Ann Richmond, Ph.D

Institution

Vanderbilt University

immunology

molecular cancer

Kevin Dalby

Institution

University of Texas at Austin

anti-cancer agent

molecular pathway

Similar Faculty Members

Besim Ogretmen, Ph.D

Institution

Medical University of South Carolina

cancer pathogenesis

cancer biology

Rafael Fridman

Institution

Wayne State University

proteases

cancer biology

Lee Graves

Institution

University of North Carolina at Chapel Hill

molecular biology

pharmacology

Adrienne Cox

Institution

University of North Carolina at Chapel Hill

molecular cancer

carcinogenesis

Dafna Bar-Sagi

Institution

New York University

oncogene

oncogene function

Shantu Amin

Institution

Pennsylvania State University

cancer letter

polycyclic aromatic hydrocarbon

Raul A. Urrutia, MD

Institution

Medical College of Wisconsin

epigenetics

histone deacetylase

Michael Hollingsworth

Institution

University of Nebraska Medical Center

pathology

immunology

Ann Richmond, Ph.D

Institution

Vanderbilt University

immunology

molecular cancer

Kevin Dalby

Institution

University of Texas at Austin

anti-cancer agent

molecular pathway